Eli Lilly and Co. and Amgen have entered a global antibody manufacturing collaboration to significantly increase the supply capacity available for Lilly’s potential COVID-19 therapies. Lilly is studying several potential neutralizing antibodies for the prevention and/or treatment of COVID-19 as either monotherapy or in combination. The two companies will have the ability to quickly scale up production should one or more of Lilly’s antibody therapies prove successful in clinical testi...